News
FDA Announces Class I Recall of Certain Infusion Set Needles
The U.S. Food and Drug Administration today announced a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets and Exel/Exelint “Securetouch+” Safety Huber Infusion Sets, manufactured by Nipro Medical Corporation for Exelint International Corporation.
Novo Nordisk's Victoza® Receives FDA Approval
Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza® (liraglutide [rDNA origin] injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
Lexicon to Host Conference Call and Webcast
Lexicon Pharmaceuticals, Inc. will hold a conference call on Thursday, January 28, 2010 at 11:30 am Eastern Time to discuss its recent top-line Phase 2 clinical results with LX4211, Lexicon's once-per-day, orally-delivered, small molecule drug candidate for the treatment of type 2 diabetes mellitus.
FDA Approves New Treatment for Type 2 Diabetes
The U.S. Food and Drug Administration today approved Victoza (liraglutide), a once-daily injection to treat type 2 diabetes in some adults.
Victoza is intended to help lower blood sugar levels along with diet, exercise, and selected other diabetes medicines. It is not recommended as initial therapy in patients who have not achieved adequate diabetes control on diet and exercise alone.
Changes in Position of Insulin Pumps Impacts Accuracy of Insulin Delivery
Researchers at Sansum Diabetes Research Institute and University of California, Santa Barbara have concluded that changing the height of a conventional insulin pump in relation to its tubing and infusion set can significantly impact expected insulin delivery rates. Such changes can occur during routine daily activities like dressing, sleeping or showering. The study, "Siphon Effects of Continuous Subcutaneous Insulin Infusion Pump Delivery Performance," evaluated the siphon or hydrostatic pressure action effects on continuous subcutaneous insulin infusion and was published in the January issue of Journal of Diabetes Science and Technology.
MDRNA, Inc. Announces Allowance of Patent Covering Rapid Acting Insulin
MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that the European Patent Office intends to grant a patent for application EP06826368 covering formulations for the intranasal delivery of rapid acting insulin, and its use for the treatment of diabetes.
ADA Welcomes Newest Volunteer Leader
The American Diabetes Association, the nation's largest and leading voluntary health organization in the fight against diabetes, is pleased to announce the newest member of its Research Foundation Board of Directors for 2010 Kenneth Moritsugu, MD, MPH of Falls Church, Virginia. Moritsugu, a native of Honolulu, Hawaii, is the current Chairman of the Johnson & Johnson Diabetes Institutes and Vice President for Global Strategic Affairs of the Johnson & Johnson Family of Diabetes Companies. Moritsugu had a 37 year career in the Commissioned Corps of the US Public Health Service. He was the Acting Surgeon General of the United States in 2002 and 2006-2007, in addition to serving as Deputy Surgeon General to Dr. David Satcher and Dr. Richard Carmona.
Patient Advocacy Partners Forge Collaboration
Fast Forward, LLC, the commercial drug development arm of the National Multiple Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF), the leader in research leading to a cure for type 1 diabetes in the world today announced a collaborative partnership with Axxam SpA -- a leading company in conducting early-stage discovery research programs for the life science industry -- to develop new treatments for two autoimmune diseases, multiple sclerosis (MS) and type 1 diabetes (T1D).
Diabetes Accounted for $218 Billion in Costs in 2007
A new analysis found that the cost of diabetes and pre-diabetes reached $218 billion in 2007, with the exploding number of cases of type 2 diabetes responsible for the majority of the costs. The National Changing Diabetes® Program (NCDP), a program of Novo Nordisk, commissioned the analysis, published online as a Web First article today in Health Affairs and performed by researchers at The Lewin Group.
Spherix Completes Enrollment in NEET
Spherix Inc., an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced the completion of patient enrollment in its global Phase 3 clinical trial NEET (70971-004), which is evaluating the safety and efficacy of D-tagatose as an oral treatment for Type 2 diabetes mellitus. The company expects the efficacy results to be available as soon as mid-year, with the maintenance phase of the trial continuing through 2010.